Navigation Links
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Date:3/13/2008

Presentation Scheduled for Monday, March 17th at 11:30am ET

NEW YORK, March 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, and Eric Grossman, MD, the Company's Vice President, Medical Affairs, are scheduled to present at the Cowen and Company Health Care Conference being held in Boston.

The presentation, which will take place on Monday, March 17th at 11:30am ET, will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
4. Keryx Biopharmaceuticals Announces Additions to Management Team
5. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
10. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...tientswithadvanced-stage,orrecurrentendometrialcan.../-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(the"C...ndocrinetherapyandoncology,todayannouncedpositivee...cpeptideconjugate,AEZS-108(formerlyAN-152),inpatie...sonalizedhealthcareapproach,thestudyselectedpatien...
(Date:11/24/2009)...irstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )todaya...irman,willpresentatthe21stAnnualPiperJaffrayHealth...9at10:00a.m.ET. ,, Toaccesstheliveandsubsequent...rRelationssectionofGenomicHealth,swebsiteat http:/...siteatleast15minutespriortothebeginningofthepresen...
(Date:11/24/2009)...CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC)manag...areConference.TheconferencewillbeheldDecember1-2,2...nTuesday,December1at11:00a.m.EasternTimeinHolmes1(...beavailableat www.celltherapeutics.com ,anditwilla...yHealthCareConference,NewYorkPalaceHotel,Holmes1(4...
(Date:11/23/2009)...n layer in which the carbon atoms are arranged on ...n nanotubes are rolled-up sheets of graphene, and ...hene boasts some very special characteristics it ...conductor, and reconciles such conflicting qualiti...hene is impermeable to gases, which makes it inter...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2Polymer with honeycomb structure 2
...14 /PRNewswire-FirstCall/,-- Abbott (NYSE: ABT ) ... they,have entered into an agreement for Abbott to...lcium), a medication used along with diet to,reduc...ment, Abbott will obtain the non-exclusive,right t...ted States,excluding Puerto Rico. Specific financi...
...s Biotech Group (USA),Inc. (the "Company" or "Tien...ced financial results for the second quarter and s...arter ended June 30, 2008, revenue was $19.7 milli...for the same period in 2007., Net income for the ...to,net income of $5.0 million for the second quart...
....,(OTC Bulletin Board: DSCI), a provider of advanc... the second quarter and first six months ended,Jun... increased volume and,distribution capacity provid... as the increased sales of its new flagship produc...he company reported sales of $13,083,966, up,from ...
Other Biology Technology:Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R) 2Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R) 3Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R) 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 13Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 14Derma Sciences Reports Second Quarter 2008 Results 2Derma Sciences Reports Second Quarter 2008 Results 3Derma Sciences Reports Second Quarter 2008 Results 4Derma Sciences Reports Second Quarter 2008 Results 5
(Date:11/24/2009)... , This release is available in Spanish . ,...re higher levels of inflammatory substances in the...eight; as shown by a research project of the Unive...Soto, a scientist at the School of Pharmacy. , T...mic study in relation to the control of body weigh...
(Date:11/23/2009)... , , Cambridge, Mass. November 23, 2009 Appli...plantain lily ( Hosta lancifolia ), a characterist... closely packed ripples along the edges. The simpl...tion resulting from bending during differential gr...que, stretching foam ribbons. , Haiyi Liang, a p...
(Date:11/23/2009)... , IRVINE, Calif. -- More than 160 participants g...Academies Keck FUTURES INITIATIVE conference. This...er scientists, engineers, and medical researchers ... issues surrounding the emerging field of syntheti...ecular biology at Princeton University and this ye...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 49293 1American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 49293 2Florida Dermatologists Announce Distinguished Service Award Winner 49289 1AMERIGROUP Corporation to Present at the 19th Annual Wachovia Mid Year Equity Conference on June 24 49288 1
...earchers showed for the first time that a natural ...help destroy pancreatic cancer cells by reaching t...and crippling its function. The study is published...Experimental Medicine and Biology. , The study al...re doubly assaulted -- pre-treated with the antiox...
...imal species in the world are insects. The largest...). Beetles can be very beautiful and colorful, but... pests that can destroy food plants like potatoes ...eas of forest. Altogether, insect pests cause U.S.... and beetles are responsible for a substantial par...
...ss., March 25, 2008 -- Scientists at Harvard Unive... invertebrate animals called bdelloid rotifers are...surviving and continuing to reproduce after doses ...d by any other animal species studied to date. , ...adiation have been implicated in inflammation, can...
Other Biology News:Mounting evidence shows red wine antioxidant kills cancer 2Mounting evidence shows red wine antioxidant kills cancer 3Common aquatic animals show extreme resistance to radiation 2
5X StabilCoat Immunoassay Stabilizer from SurModics, Inc.
Mouse Anti-Human PARK2 Monoclonal Antibody, Unconjugated, Clone 1H4 from Novus Biologicals
Pokeweed Mitogen Spleen Cell Conditioned Medium, 25 mL from StemCell Technologies, Inc.
Mouse Anti-Human FMN2 Monoclonal Antibody, Unconjugated, Clone 4B8 from Novus Biologicals
Biology Products: